Annual report pursuant to Section 13 and 15(d)

Statement of Stockholders??? Equity

v3.10.0.1
Statement of Stockholders’ Equity - USD ($)
Series A and Z Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Other Comprehensive Loss
Total
Beginning balance, shares at Dec. 31, 2016 115,894 0        
Beginning balance, amount at Dec. 31, 2016 $ 116 $ 0 $ 4,703,848 $ (1,872,908) $ 0 $ 2,831,056
Conversion of preferred stock to common stock, shares (115,894) 8,335,080        
Conversion of preferred stock to common stock, amount $ (116) $ 8,335 (8,219)     0
Issuance of common stock at $6 per share for cash, net of $32,400 issuance costs, shares   789,674        
Issuance of common stock at $6 per share for cash, net of $32,400 issuance costs, amount   $ 790 4,704,856     4,705,646
Tactic Pharma shares surrendered, shares   (2,888,727)        
Tactic Pharma shares surrendered, amount   $ (2,889) 2,889     0
Shares issued in Gem transaction, net of issuance costs of $169,257, shares   3,055,394        
Shares issued in Gem transaction, net of issuance costs of $169,257, amount   $ 3,055 18,329,310     18,332,365
Non-cash stock compensation     305,205     305,205
Net loss       (16,554,872)   (16,554,872)
Ending balance, shares at Dec. 31, 2017 0 9,291,421        
Ending balance, amount at Dec. 31, 2017 $ 0 $ 9,291 28,037,889 (18,427,780) 0 9,619,400
Shares issued in Gem transaction, net of issuance costs of $169,257, amount           0
Non-cash stock compensation     529,332     529,332
Net loss       (3,227,932)   (3,227,932)
Accumulated other comprehensive loss         (2,396) (2,396)
Ending balance, shares at Dec. 31, 2018 0 9,291,421        
Ending balance, amount at Dec. 31, 2018 $ 0 $ 9,291 $ 28,567,221 $ (21,655,712) $ (2,396) $ 6,918,404